ATRA (STOCKS)
Atara Biotherapeutics, Inc
$8.510000
-0.715000 (-7.75%)
Prev close: $9.225000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Anhco Nguyen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $83.99M
- Employees
- 38
- P/E (TTM)
- -10.45
- P/B (TTM)
- -2.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.29 | $-0.41 | +0.1231 | +29.80% |
|
Dec 2025 (Q4)
|
$-0.25 | $-0.17 | -0.0752 | -43.02% |
|
Sep 2025 (Q3)
|
$-0.32 | $-0.88 | +0.5572 | +63.52% |
|
Jun 2025 (Q2)
|
$0.19 | $-0.47 | +0.6592 | +140.49% |
Financial Statements
| Revenues | $23.14M |
| Benefits Costs and Expenses | $32.58M |
| Costs And Expenses | $29.45M |
| Operating Expenses | $29.45M |
| Depreciation and Amortization | $350.00K |
| Research and Development | $10.18M |
| Other Operating Expenses | $19.19M |
| Operating Income/Loss | -$6.31M |
| Income/Loss From Continuing Operations After Tax | -$9.47M |
| Income/Loss From Continuing Operations Before Tax | -$9.44M |
| Income Tax Expense/Benefit | $31.00K |
| Interest Expense, Operating | $3.61M |
| Net Income/Loss | -$9.47M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$9.47M |
| Net Income/Loss Available To Common Stockholders, Basic | -$9.47M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.76 |
| Diluted Earnings Per Share | -$0.78 |
| Basic Average Shares | 40,201,000 |
| Diluted Average Shares | 40,354,000 |
| Assets | $20.00M |
| Current Assets | $12.17M |
| Noncurrent Assets | $7.82M |
| Fixed Assets | $55.00K |
| Other Non-current Assets | $7.77M |
| Liabilities | $57.31M |
| Current Liabilities | $5.65M |
| Accounts Payable | $637.00K |
| Wages | $629.00K |
| Other Current Liabilities | $4.38M |
| Noncurrent Liabilities | $51.66M |
| Equity | -$37.31M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$37.31M |
| Liabilities And Equity | $20.00M |
| Net Cash Flow From Operating Activities | -$25.88M |
| Net Cash Flow From Operating Activities, Continuing | -$25.88M |
| Net Cash Flow From Investing Activities | $1.07M |
| Net Cash Flow From Investing Activities, Continuing | $1.07M |
| Net Cash Flow From Financing Activities | $19.30M |
| Net Cash Flow From Financing Activities, Continuing | $19.30M |
| Net Cash Flow | -$5.51M |
| Net Cash Flow, Continuing | -$5.51M |
| Comprehensive Income/Loss | -$9.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$9.47M |
| Other Comprehensive Income/Loss | $0.00 |